রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।
Rimactazid 300mg is indicated for the treatment and prevention of all forms of tuberculosis (TB), particularly in patients who require a combination of rifampicin and isoniazid.
Rimactazid is a fixed-dose combination of rifampicin and isoniazid. Rifampicin inhibits bacterial DNA-dependent RNA polymerase, preventing RNA synthesis. Isoniazid interferes with the synthesis of mycolic acid, essential for mycobacterial cell wall formation. The combination provides synergistic bactericidal activity against Mycobacterium tuberculosis.
Dose depends on body weight and treatment stage.
Common adult dose: 1 tablet daily on an empty stomach, ideally in the morning.
Should be used as part of a full anti-TB regimen.
Do not skip doses or stop treatment prematurely.
Rifampicin induces hepatic enzymes, which can reduce the efficacy of oral contraceptives, warfarin, corticosteroids, and some antiretrovirals.
Avoid alcohol to reduce liver toxicity risks.
Isoniazid may increase levels of phenytoin and carbamazepine.
Hypersensitivity to rifampicin, isoniazid, or other rifamycins.
Severe hepatic dysfunction.
History of drug-induced hepatitis.
Common: Nausea, vomiting, red-orange discoloration of urine, fatigue, rash.
Serious: Hepatotoxicity, peripheral neuropathy, hypersensitivity reactions, thrombocytopenia.
Use in pregnancy only when benefits outweigh risks; rifampicin may increase bleeding tendency.
Both rifampicin and isoniazid pass into breast milk but are generally considered safe during lactation.
Monitor liver function before and during therapy.
Supplement vitamin B6 (pyridoxine) to reduce neuropathy risk.
Advise patients of urine and body fluid discoloration.
Ensure adherence to full TB regimen to prevent resistance.
Antitubercular fixed-dose combinations
Store below 25°C in a dry place, protected from light. Keep out of reach of children.